ClinicalTrials.gg

Program

ethinyl estradiol, levonorgestrel drug combination

Also written as “Microgynon”, “Microgynon®” and “Ethinyl estradiol/levonorgestrel”.

Its studies are mostly in Tuberculosis · Dyslipidemias · Hematologic Neoplasms · Multiple Sclerosis, led by 2 companies.

Furthest: phase 4, since Mar 30, 20122 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HRA Pharma10 open or runningphase 4since Mar 30, 2012Mar 30, 2012none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 1since Nov 14, 2018Nov 14, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2012First study: phase 4 study in Emergency ContraceptionNew to HRA PharmaHRA Pharma · NCT01569113 · 76 enrolled · Netherlands, Sweden, United Kingdom
  2. Nov 14, 2018Merck KGaA, Darmstadt, Germany’s first study: phase 1 study in Multiple SclerosisNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03745144 · 28 enrolled · Germany, Poland

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03745144Multiple Sclerosis · Germany, Poland1CompletedMerck KGaA, Darmstadt, GermanySep 2, 202228
NCT01569113Emergency Contraception · Netherlands, Sweden, United Kingdom4CompletedHRA PharmaAug 201276

How it is read

Names in the registry

  • “Microgynon”, 3 entries
  • “Microgynon®”, 2 entries
  • “Ethinyl estradiol/levonorgestrel”, 1 entry
  • “ethinyl estradiol/levonorgestrel”, 1 entry
  • “Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ethinyl estradiol, levonorgestrel drug combination (HRA Pharma): development program | ClinicalTrials.gg